Senest indskrevne ph.d.-studerende står øverst.
Use of Real-World Data in screening for unknown drug effects and drug utilisation patterns within dermatology
Monitoring of marketed drugs is an important part of the ongoing evaluation of the benefits and risks of drugs, and epidemiological analyzes of healthcare data have been proposed as an alternative to traditional side-effect monitoring.
In this project, epidemiologic screening of large healthcare databases will be applied to evaluate its use within dermatology, by conducting: 1) A study screening all dermatology drugs for adverse and beneficial effects, by using self-controlled designs and a nested case-control analysis. 2) A study screening all marketed drugs for dermatological adverse outcomes using the same designs. 3) A comprehensive dermatology drug utilisation study screening for unexpected utilisation patterns.
Main supervisor: Jesper Hallas
Public Health Research in the Danish Community Pharmacy setting
Alaa Hassan Burghle
In Denmark, patients can go to any community pharmacy, with no appointment, and receive counselling on the safe and effective use of medication. In addition to the usual counselling a number of pharmaceutical care services are provided. This setting makes the community pharmacy an excellent data-provider for research projects as its platform can e.g. be used to collect information from patients on side effects not otherwise available through other means or targeting inappropriate use of medications through pharmaceutical care. With this PhD-thesis we aim to further explore and strengthen the possibility of conducting public health research projects in the Danish community pharmacy setting. We will achieve this through the conduct of three research projects, each utilizing different methods: a randomized controlled trial, a qualitative study, and a survey.
Main Supervisor: Anton Pottegård
Implementation of personalized medicine in everyday practice: Preventing serious adverse reactions from chemotherapy.
Niels Herluf Paulsen
This project aims to substantially reduce the risk of serious adverse reactions in patients receiving 5-fluorouracil (5-FU) for cancer. The project will use a gene test to preemptively adjust the dose of 5-FU for each patient and hereby reducing the risk of risk of severe adverse reactions. This project may serve as a proof-of-concept for implementation of personalized medicine in everyday cancer treatment.
Main supervisor: Per Damkier
Pharmacoepidemiological aspects of low-dose or off-label treatment with antipsychotics: Utilization and consequences
This PhD project uses register data to explore diagnoses associated with use of antipsychotics (psychiatric and non-psychiatric), and furthermore to investigate the potential acute and long-term risks associated with low-dose antipsychotic treatment.
Main supervisor: Jesper Hallas
Attitudes towards deprescribing in older patients with limited life expectancy: The perspective of patients, relatives, and health care professionals
This PhD project aims to explore attitudes towards deprescribing from the perspective of patients, relatives, and health care professionals, specifically focusing on older people with frailty and those approaching the last part of life. We will do this through systematic reviews and qualitative studies. Further, we will translate, cross-culturally adapt, and validate a questionnaire for exploring patient attitudes towards deprescribing. With this PhD project, we aim to get insight into what may facilitate and hinder deprescribing, and thus how to ultimately improve the uptake of deprescribing in clinical practice.
Main supervisor: Anton Pottegård
CYP2D6 genotype-phenotype determination for improved personalized medicine
The objective of this project is to establish the clinical function level of the most frequent CYP2D6 alleles through population pharmacokinetic modelling of different CYP2D6 substrates. Ultimately, the aim is to find an optimal method for translating CYP2D6 genotypes into phenotypes for improved personalized medicine. The project is conducted in collaboration with H. Lundbeck A/S.
Main supervisor: Kim Brøsen
Co-supervisor: Tore Bjerregaard Stage